Business · 15/07/2020Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for ISTENT INJECT TRABECULAR MICRO-BYPASS SYSTEM
Summary
The US Food and Drug Administration (FDA) has officially confirmed the review period for the ISTENT INJECT TRABECULAR MICRO-BYPASS SYSTEM, a medical device, in accordance with patent extension regulations, following a submission to the US Patent and Trademark Office (USPTO).
Original source language: Federal Register — Food and Drug AdministrationOpen original release →